Breaking News

Polyplus Acquires French Biotechnology CDMO Bio Elpida

The teams will integrate strategically to strengthen the supply chain for GMP formulation and filling at Polyplus.

Author Image

By: Charlie Sternberg

Associate Editor

Polyplus, a solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has acquired Bio Elpida, a French biotechnology contract development and manufacturing (CDMO) company providing pre-clinical and clinical development services for cell therapy and biologics. The teams will integrate strategically to strengthen the supply chain for GMP formulation and filling at Polyplus.   “Bio Elpida is certified by the French Health Authorities (ANSM...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters